Inspire Medical Systems, Inc. (New York Stock Exchange:INSP)
| Market Cap | $1.60B-38.7% |
| Revenue (ttm) | $880.94M-0.2% |
| Net Income | $100.72M+126.0% |
| EPS | $3.44+134.3% |
| Shares Out | 28.97M |
| PE Ratio | 15.83 |
| Forward PE | 36.17 |
| Dividend | n/a |
| Ex-Dividend Date | Jan 9, 2008 |
| Volume | 552,317 |
| Open | $56.39 |
| Previous Close | $56.28 |
| Day's Range | $54.95 - $56.71 |
| 52-Week Range | $38.91 - $147.03 |
| Beta | 0.65 |
| Analysts | Hold |
| Price Target | $64.67(+17.37%) |
| Earnings Date | Feb 10, 2027 |
About INSP
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
10 firms rating INSP in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 10, 2027Earnings report
$INSP stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in INSP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INSP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INSP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
INSP Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New INSP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INSP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in INSP
| IJRiShares Core S&P Small-Cap ETF | $97.99M |
| VTIVanguard Morningstar Total Stock Market ETF | $49.28M |
| VBVanguard Morningstar Small-Cap ETF | $44.10M |
| IWMiShares Russell 2000 ETF | $42.71M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $24.71M |
| VXFVanguard Extended Market ETF | $22.41M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from INSP’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple adverse patent rulings in Europe from competitor Nyxoah outweigh positive tone from price movement and conference participation coverage.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| GRPZ | Invesco S&P SmallCap 600 GARP ETF | 2.18% |
| FDHT | FIDELITY DIGITAL HEALTH ETF | 1.99% |
| MOON | Direxion Moonshot Innovators ETF | 1.65% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 1.38% |
| HEAL | Global X HealthTech ETF | 1.29% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 0.95% |
| FSGS | First Trust SMID Growth Strength ETF | 0.87% |
| SQLV | Royce Quant Small-Cap Quality Value ETF | 0.54% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 0.50% |
| LITL | Simplify Piper Sandler US Small-Cap PLUS Income ETF | 0.48% |
| NIXT | Research Affiliates Deletions ETF | 0.47% |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 0.42% |
Weight is the stock’s share of each fund’s holdings.
